No Data
No Data
Palisade Bio to Participate in the Virtual Investor Closing Bell Series
Live video webcast on Wednesday, June 26th at 4:00 PM ET Carlsbad, CA, June 24, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), biopharmaceutical company focused on developi
Palisade Bio Dips on Linking With Strand
Palisade Bio Provides Update on Advancement of Its Strategic Collaboration With Strand Life Sciences
– Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathop
Express News | Palisade Bio Announces Canadian Intellectual Property Office Issues Notice Of Allowance For Patent Covering PALI-2108, An Orally Administered PDE4 Inhibitor Prodrug For Ulcerative Colitis
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposureCompany on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC be
Palisade Bio to Present at the Virtual Investor Pitch Conference
Live video webcast on Monday, June 17th at 12:00 PM ET Carlsbad, CA, June 10, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), biopharmaceutical company focused on developing
No Data
trailerparkolympicsOP : In case you're wondering about the name of the drug: (N)rural(S)tem (I)nc 189.